DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show

DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show
A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, updated findings from a Phase 1/2 clinical trial show. “We believe these results highlight DPX-Survivac’s potential to alter the treatment landscape in advanced ovarian cancer and support its continued development,” Joanne Schindler, MD, chief medical officer at IMV, said in a press release. The results were presented recently by Oliver Dorigo, MD, PhD, the trial’s principal investigator, at the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program. The poster is titled “Infiltration of of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa).” DPX-Survivac is a new class of T-cell immunotherapy designed to stimulate the immune system to target and destroy cancer cells, specifically those that have at their surface a protein called 
Subscribe or to access all post and page content.